Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ensoma

News headline image
Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy
From Ensoma
Via Business Wire
News headline image
Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD
From Ensoma
Via Business Wire
News headline image
Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025
From Ensoma
Via Business Wire
News headline image
Ensoma to Present New Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
From Ensoma
Via Business Wire
News headline image
Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
From Ensoma
Via Business Wire
News headline image
Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy
From Ensoma
Via Business Wire
News headline image
Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting
From Ensoma
Via Business Wire
News headline image
Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
From Ensoma
Via Business Wire
News headline image
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
From Ensoma
Via Business Wire
News headline image
Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer
From Ensoma
Via Business Wire
News headline image
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
From Ensoma
Via Business Wire
News headline image
Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
From Ensoma
Via Business Wire
News headline image
Ensoma Announces Closing of Twelve Bio Acquisition
From Ensoma
Via Business Wire
News headline image
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
From Ensoma
Via Business Wire
News headline image
Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies
From Ensoma
Via Business Wire
News headline image
Ensoma Appoints Cell and Gene Therapy Pioneer Emile Nuwaysir, Ph.D., as Chief Executive Officer
From Ensoma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.